Data sources on drug safety evaluation: A review of recent published meta-analyses

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 1, 2012, Pages 21-33

  Alves, Carlos ^a,b,c   Batel Marques, Francisco ^a,b   Macedo, Ana Filipa ^a,c  

^a ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

Adverse events; Experimental studies; Meta analysis; Observational studies; Pharmacovigilance

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; CELECOXIB; CITALOPRAM; DICLOFENAC; DIPYRIDAMOLE; ERYTHROPOIETIN; ESCITALOPRAM; ETORICOXIB; FLUOXETINE; IBUPROFEN; INDOBUFEN; INDOMETACIN; LUMIRACOXIB; MELOXICAM; NAPROXEN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PAROXETINE; PIROXICAM; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; ROFECOXIB; ROSIGLITAZONE; SERTRALINE; TRIFLUSAL; UNINDEXED DRUG; VALDECOXIB; WARFARIN; XIMELAGATRAN;

ANEMIA; ANXIETY DISORDER; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CASE CONTROL STUDY; DRUG ELUTING STENT; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EXPERIMENTAL STUDY; HEART INFARCTION; HUMAN; MAJOR DEPRESSION; MEDICAL LITERATURE; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

GUIDELINES AS TOPIC; HUMANS; META-ANALYSIS AS TOPIC; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACEUTICAL PREPARATIONS; PHARMACOVIGILANCE; RESEARCH DESIGN; RISK;

EID: 84855344908     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2260     Document Type: Article

References (49)

1. Bates DW. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. JAMA 1995; 274(1): 29-34.
2. Akici A, Okta S. Rational pharmacotherapy and pharmacovigilance. Curr Drug Saf 2007; 2(1): 65-69.
3. Hopewell S, Wolfenden L, Clarke M. Reporting of adverse events in systematic reviews can be improved: survey results. J Clin Epidemiol 2008; 61(6): 597-602.
4. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008; 336(7655): 1227-1231.
5. Hicks LK, Haynes AE, Reece DE, et al. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev 2008; 34(5): 442-452.
6. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7(3): 177-188.
7. Kim CJ, Berlin JA. The use of meta-analysis in pharmacoepidemiology. In Textobook of pharmacoepidemiology, Strom BL, Kimmel SE (eds). John Wiley & Sons: Chichester, England, 2006; 353-365.
8. Strom BL. Study designs available for pharmacoepidemiology studies. In Textobook of pharmacoepidemiology, Strom BL, Kimmel SE (eds). John Wiley & Sons: Chichester, England, 2006; 13-23.
9. Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet 2004; 363: 1728-1731.
10. Vandenbroucke JP, Psaty BM. Benefits and risks of drug treatments: how best to combine the best evidence on benefits with the best data about adverse effects. JAMA 2008; 300(2): 2417-2419.
11. Ioannidis JP, Evans SJ, Gøtzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004; 141(10): 781-788.
12. Madre LK, Califf RM, Reynolds RF, et al. Views of Academia, Industry, and Regulatory Agencies. In Textobook of pharmacoepidemiology, Strom BL, Kimmel SE (eds). John Wiley & Sons: Chichester, England, 2006; 63-88.
13. Ioannidis JPA, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001; 285: 437-443.
14. Vandenbroucke JP. Benefits and harms of drug treatments. BMJ 2004; 329(7456): 2-3.
15. Loke YK, Derry S, Aronson JK. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. Br J Clin Pharmacol 2004; 57(5): 616-621.
16. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?" Lancet 2005; 365(9453): 82-93.
17. Papanikolaou PN, Christidi GD, Ioannidis JPA. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 2006; 174(5): 635-641.
18. Kim CJ, Berlin JA. The Use of Meta-analysis in Pharmacoepidemiology. In Textobook of pharmacoepidemiology, Strom BL, Kimmel SE (eds). John Wiley & Sons: Chichester, England, 2006; 353-365.
19. Science journal citation reports ISI. Thomson Reuters Web site. (accessed 30 March 2011).
20. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. London: European Medicines Agency, 1995. (accessed 16 July 2011).
21. WHO Collaboration Centre for Drug Statistics Methodology. ATC/DDD Index 2011. (accessed 30 March 2011).
22. MSSO Medical Dictionary for Regulatory Activities. MedDRA v14.0. (accessed 18 July 2011).
23. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17(1): 1-12.
24. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Higgins JPT, Green S (eds). The Cochrane Collaboration, March 2011. (accessed 30 March 2011).
25. Downs SH, Black N. The feasibility of creating a checklist for assessment of the methodological quality of both the randomised and nonrandomised studies of health care interventions. J Epidemiol Community Health 1998; 52(6): 377-384.
26. Wells G, Shea B, O'Connell D, et al. The Newcaslte-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. (accessed 30 March 2011).
27. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
28. Cochrane adverse effects subgroup. Including adverse effects. In Cochrane handbook for systematic reviews of interventions, Loke YK, Price D, Herxheimer A (eds). John Wiley & Sons: Chichester, England, 2006; Appendix 6b.
29. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analysis of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analysis. Lancet 1999; 354: 1896-1900.
30. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analysis: The PRISMA Statement. PLoS Med 2009; 6(7): e100097. DOI: 10.1371/journal.pmed.100097
31. Matchar DB, McCroy DC, Orlando LA, et al. Comparitive Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension. Comparative Effectiveness Review No. 10. (Prepared by Duke Evidence-based Practice Center under Contract no.280-02-0025.); Agency for Healthcare Research and Quality, Rockville, MD; November 2007. (accessed 30 March 2011).
32. LaCroix AZ, Cauley JA, Pettinger M, et al. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med 2003; 139: 97-104.
33. Tromp AM, Plujim SM, Smit JH, et al. Fall-risk screening test: a prospective study on predictors for falls in community-dwelling elderly. J Clin Epidemiol 2001; 54(8): 837-844.
34. van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001; 16: 581-588.
35. Scolnik D, Nulman I, Rovet J, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994; 271: 767-770.
36. Jüni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999; 282(11): 1054-1060.
37. Sterne JAC, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 2001; 323(7304): 101-105.
38. Bax L, Moons KG. Beyond publication bias. J Clin Epidemiol 2010; 64(5): 459-462.
39. Hennessy S, Berlin JA, Kinman JL, et al. Risk of venous thromboembolism form oral contraceptives containing gestodene and desogestrel versus levonogestrel: a meta-analysis and formal sensitivity analysis. Contraception 2001; 64: 125-133.
40. Gagne JJ, Griesdale DEG, Schneeweiss S. Aprotin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: a meta-analysis of epidemiologic studies. Pharmacoepidemiol Drug Saf 2009; 18: 259-268.
41. Loke YK, Jeevanantham V, Singh S. Biphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 2009; 32(3): 219-228.
42. Toh S, Hernández-Díaz S. Statins and fracture risk: a systematic review. Pharmacoepidemiol Drug Saf 2007; 16: 627-640.
43. Chen LC, Ashcroft DM. Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials. J Clin Pharm Ther 2006; 31: 565-576.
44. Bradburn MJ, Deeks JJ, Berlin JA, Localio AR. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007; 26: 53-77.
45. Crowe BJ, Xia HA, Berlin JA, et al. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team. Clin Trials 2009; 6: 430-440.
46. International Conference on Harmonisation. E9: statistical principles for clinical trials. 1998. (accessed 23 July 2011).
47. Behrman RE, Benner JS, Brown JS, et al. Developing the Sentinel System - A National Resource for Evidence Development. N Engl J Med 2011; 364(6): 498-499.
48. DIA/FDA Best practices for regulatory information synthesis of randomized controlled trials for product safety evaluation. March 10-11, 2011. (accessed 23 July 2011).
49. The Cochrane Collaboration. Methodology Review Group. (accessed 23 July 2011).